Results 241 to 250 of about 124,093 (287)
Sildenafil and phosphodiesterase-5 inhibitors for heart failure
Current Heart Failure Reports, 2008 Treatment of heart failure (HF) is a challenging task. An impaired nitric oxide pathway contributes to several abnormal cardiac and vascular phenotypes typical of the failing cardiovascular system. Inhibition of phosphodiesterase-5 (PDE5) is a new therapeutic strategy for overexpressing nitric oxide signaling by increasing the availability of cyclic ...
M. Guazzi
openaire +3 more sources
Design of Second Generation Phosphodiesterase 5 Inhibitors
Current Topics in Medicinal Chemistry, 2007 The clinical significance of phosphodiesterase 5 (PDE5) inhibition is increasingly understood following the pioneering work with sildenafil, and the continuing development programmes for both sildenafil and other marketed inhibitors. Since the initial launch of sildenafil for male erectile dysfunction (MED), approval has now been granted for treatment ...
Michael J, Palmer +3 more
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
In Defense of Phosphodiesterase 5 Inhibitors
JAMA Ophthalmology, 2022Not ...
Belladelli, Federico +2 more
openaire +3 more sources
Phosphodiesterase 5 inhibitors: current status and potential applications
Nature Reviews Drug Discovery, 2002 Phosphodiesterase enzymes convert cyclic GMP and cyclic AMP to the corresponding nucleotide monophosphates. Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men,
Rotella, David, David P. Rotella
exaly +2 more sources
ADMET considerations for phosphodiesterase-5 inhibitors
Expert Opinion on Drug Metabolism & Toxicology, 2012ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling is an important aspect of all drug developments. The pharmaceutical industry must always consider ADMET properties in order to optimize drug candidates and to introduce new formulations against existing marketed drugs.
Mohammad Amin, Rezvanfar +2 more
openaire +2 more sources
Phosphodiesterase-5 Inhibitors
2013Nitric oxide (NO) signaling plays a key role in modulating vascular tone and remodeling in the pulmonary circulation. The guanylate cyclase/cyclic guanylate monophosphate-signaling pathway primarily mediates nitric oxide signaling. This pathway is critical in normal regulation of the pulmonary vasculature, and is an important target for therapy in ...
Barbara A, Cockrill, Aaron B, Waxman
openaire +2 more sources
Reno-protective effects of Phosphodiesterase 5 inhibitors
Clinical and Experimental Nephrology, 2021The kidneys are vital organs that play an important role in removing waste materials from the blood, electrolyte balance, blood pressure regulation, and red blood cell genesis. Kidney disease can be caused by various factors, including diabetes, ischemia/reperfusion injury, and nephrotoxic agents.
Enis Rauf Coskuner, Burak Ozkan
openaire +2 more sources
Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
Annals of Pharmacotherapy, 2005OBJECTIVE To review the pharmacologic and clinical trial data of the Food and Drug Administration–approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction (ED). DATA SOURCES Primary research and review ...
Stephen M, Setter +4 more
openaire +2 more sources
A chemometric study of phosphodiesterase 5 inhibitors
Journal of Molecular Graphics and Modelling, 2006This work presents a chemometric classification for a set of phosphodiesterase 5 inhibitors, based on a pattern recognition method widely used in quantitative structure-activity (QSAR) studies, hierarchical cluster analysis (HCA) and principal component analysis (PCA), aiming to access the most relevant structural and physicochemical variables related ...
Luciana Jansen, de O Figueiredo +4 more
openaire +2 more sources
Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design, 2009PDE-5 inhibitors were originally studied in cardiovascular indications but were later developed and approved for on-demand treatment of erectile dysfunction (ED). A few years ago sildenafil was approved for the treatment of pulmonary hypertension, thus renewing interest in cardiovascular applications, and tadalafil became available in once-daily ...
Giannitsas, Konstantinos +1 more
openaire +2 more sources